文献速递肥胖与代谢综合征糖尿病

双重GIP/GLP1受体激动剂替尔泊肽治疗2例Alström综合征(一种罕见肥胖综合征)的有效性

Effectiveness of the Dual GIP/GLP1-Agonist Tirzepatide in 2 Cases of Alström Syndrome, a Rare Obesity Syndrome.
PubMed 文献 · J Clin Endocrinol Metab · 2025-01-01

本文报告了首2例接受替尔泊肽治疗的Alström综合征患者。例1为23岁男性,治疗18个月,体重下降28 kg(113.6降至83 kg,-26.9%),糖化血红蛋白下降0.4%(6.7%降至6.3%),每日胰岛素剂量减少96 IU/天(-83%),肝脂肪分数由20%经MRI确认消退。例2为20岁男性,随访9个月,体重下降9.5 kg(132降至122.5 kg,-7.2%),肝脂含量由21%降至11%。

要点

  • 例1治疗18个月体重下降26.9%、HbA1c下降0.4%、胰岛素剂量减少83%。
  • 例1肝脂肪分数由20%经MRI确认消退。
  • 例2随访9个月体重下降7.2%、肝脂含量由21%降至11%。

核心结论

  • 替尔泊肽在Alström综合征的体重、代谢功能障碍相关脂肪性肝病和胰岛素抵抗方面显示出很大有效性。
  • 作者指出需在更大队列中进行随访研究以确认这些发现。

研究设计与样本

  • 本文报告首2例接受替尔泊肽治疗的Alström综合征患者,2例此前均接受司美格鲁肽治疗并在作者所在诊所接受替尔泊肽治疗。

主要发现

  • 例1为23岁男性,治疗18个月,体重下降28 kg(113.6降至83 kg,-26.9%)。
  • 例1糖化血红蛋白下降0.4%(6.7%降至6.3%),每日胰岛素剂量减少96 IU/天(-83%;甘精胰岛素58降至20 IU,餐时胰岛素58降至0 IU),同时维持口服降糖药。
  • 例1既往脂肪分数20%的肝脂肪变性经磁共振成像确认消退。
  • 例2为20岁男性,既往糖尿病控制良好,随访9个月,体重下降9.5 kg(132降至122.5 kg,-7.2%),肝脂含量由最近一次MRI的21%降至约3个月治疗后的11%。

关键数值与推荐

  • 例1:体重-28 kg(113.6降至83 kg,-26.9%),HbA1c -0.4%(6.7%降至6.3%),胰岛素-96 IU/天(-83%)。
  • 例1:甘精胰岛素58降至20 IU,餐时胰岛素58降至0 IU。
  • 例1:肝脂肪分数20%经MRI确认消退。
  • 例2:体重-9.5 kg(132降至122.5 kg,-7.2%),肝脂含量21%降至11%。

临床怎么用

  • 原文未据此给出推荐。
  • 作者指出替尔泊肽在Alström综合征的体重、代谢功能障碍相关脂肪性肝病和胰岛素抵抗方面显示出很大有效性。
  • 作者指出需在更大队列中进行随访研究以确认这些发现。

局限性

  • 作者指出需在更大队列中进行随访研究以确认这些发现。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Tirzepatide, a dual glucose-dependent insulinotropic peptide/glucagon-like peptide 1 (GIP/GLP1) receptor agonist, was recently approved for type 2 diabetes and weight management. Alström syndrome (AS) is a rare, genetic, multisystemic disorder, characterized by cone-rod dystrophy, progressive hearing loss, obesity, and diabetes with profound insulin resistance due to marked hyperphagia. OBJECTIVE: Here we highlight the potential of tirzepatide as a novel therapeutic option for improving glycemic outcomes, metabolic dysfunction-associated steatotic liver disease (MASLD), and effectively reducing body weight in individuals with AS. METHODS: We present the first 2 reported cases of people living with AS treated with tirzepatide. RESULTS: Two individuals with AS, previously treated with semaglutide, received tirzepatide at our clinic. The first, a 23-year-old man with 18 months of treatment, experienced a weight loss of -28 kg (113.6 to 83 kg, -26.9%); glycated hemoglobin A1c decreased by -0.4% (6.7% to 6.3%), with considerable reductions in daily insulin doses of -96 IU/day (-83%; 58 to 20 IU insulin glargine and 58 to 0 IU prandial insulin), while maintaining oral antidiabetics. Hepatic steatosis, with a previous fat fraction of 20%, resolved as confirmed by magnetic resonance imaging (MRI). The second, a 20-year-old man with previously well-controlled diabetes, was followed up for 9 months and showed a weight reduction of -9.5 kg (132 kg to 122.5 kg; -7.2%) with a reduction of hepatic lipid content from 21% at the latest MRI to 11% after approximately 3 months of therapy. CONCLUSION: Tirzepatide shows great effectiveness with regard to body weight, MASLD, and insulin resistance in AS. Follow-up studies with larger cohorts have to be performed to confirm these findings.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Ferch M, Peitsch I, Kautzky-Willer A, et al. Effectiveness of the Dual GIP/GLP1-Agonist Tirzepatide in 2 Cases of Alström Syndrome, a Rare Obesity Syndrome. J Clin Endocrinol Metab. 2025. PMID: 40302276. doi:10.1210/clinem/dgaf258

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。